Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

SEATTLE & NEW YORK & EMERYVILLE, Calif.–(BUSINESS WIRE)– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company
focused on re-engaging the body’s immune system to revolutionize the
treatment of cancer, announced today that it has entered into an
exclusive license agreement with Memorial Sloan Kettering Cancer Center
(MSK) and Eureka Therapeutics, Inc. for a novel, fully-human binding
domain targeting B-cell maturation antigen (BCMA), along with binding
domains against two additional undisclosed multiple myeloma targets to
be used for the potential development and commercialization of chimeric
antigen receptor (CAR) cell therapies for patients with multiple
myeloma. The binding domains were developed under a collaboration
agreement between Eureka Therapeutics and MSK. The parties expect the
BCMA CAR to enter human testing as early as 1H2017.

“We are optimistic that CAR T therapy can be an important component in
treating patients with multiple myeloma, and we are pleased to bring
additional fully-human binding domains against BCMA and other targets
into our program,” said Hy Levitsky, M.D., Juno’s Chief Scientific
Officer. “We believe that a multi-pronged approach may be necessary to
treat this disease, and we will pursue more than one target against
myeloma. The MSK and Eureka constructs are promising additions to our
portfolio that will accelerate our efforts and provide additional
opportunities to combat this disease.”

« We are pleased to work with Juno Therapeutics on developing CAR T
therapies against multiple myeloma, » said Dr. Cheng Liu, President and
Chief Executive Officer of Eureka Therapeutics. “Multiple myeloma is a
devastating disease. For the past three years, we have been working with
MSK to develop CAR T therapies against multiple myeloma, and we are
delighted that Juno is able to use their broad expertise to bring these
therapies to patients faster. »

MSK and Eureka Therapeutics are eligible to receive an undisclosed
upfront payment, additional payments upon the achievement of undisclosed
clinical, regulatory, and commercial milestones, and royalties on net
sales.

About Eureka Therapeutics, Inc.

Eureka Therapeutics Inc. is a privately held biotechnology company,
headquartered in the San Francisco Bay area, focused on developing
first-in-class T cell immunotherapies for hematological malignancies and
solid tumors. Its core technology platforms center around the discovery
and engineering of fully human antibodies against intracellular targets
via the MHCI complex. The company is developing a pipeline of novel
cancer therapeutics targeting intracellular oncogenes.

www.eurekainc.com

About Memorial Sloan Kettering

Memorial Sloan Kettering Cancer Center is the world’s oldest and largest
private institution devoted to prevention, patient care, research, and
education in cancer. Its scientists and clinicians generate innovative
approaches to better understand, diagnose, and treat cancer. Memorial
Sloan Kettering specialists are leaders in biomedical research and in
translating the latest research to advance the standard of cancer care
worldwide.

www.mskcc.org

About Juno

Juno Therapeutics is building a fully integrated biopharmaceutical
company focused on re-engaging the body’s immune system to revolutionize
the treatment of cancer. Founded on the vision that the use of human
cells as therapeutic entities will drive one of the next important
phases in medicine, Juno is developing cell-based cancer immunotherapies
based on chimeric antigen receptor and high-affinity T cell receptor
technologies to genetically engineer T cells to recognize and kill
cancer. Juno is developing multiple cell-based product candidates to
treat a variety of B-cell malignancies as well as solid tumors. Several
product candidates have shown compelling clinical responses in clinical
trials in refractory leukemia and lymphoma conducted to date. Juno’s
long-term aim is to improve and leverage its cell-based platform to
develop new product candidates that address a broader range of cancers
and human diseases. Juno brings together innovative technologies from
some of the world’s leading research institutions, including the Fred
Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer
Center, Seattle Children’s Research Institute, the University of
California, San Francisco, and The National Cancer Institute. Juno
Therapeutics has an exclusive license to the St. Jude Children’s
Research Hospital patented technology for CD19 directed product
candidates that use 4-1BB, which was developed by Dario Campana, Chihaya
Imai, and St. Jude Children’s Research Hospital.

Juno Forward-Looking Statements

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, and Section 21E of the Securities
Exchange Act of 1934, including statements regarding Juno’s business
plans, the potential of T cell therapeutics, the potential of the BCMA
binding domain and other human binders, clinical trial results and
clinical trial plans, and planned activities and potential payments
under the license agreement among Juno, Memorial Sloan Kettering, and
Eureka Therapeutics. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially from
such forward-looking statements, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to, risks associated with:
the success, cost, and timing of Juno’s product development activities
and clinical trials; Juno’s ability to obtain regulatory approval for
and to commercialize its product candidates; Juno’s ability to establish
a commercially-viable manufacturing process and manufacturing
infrastructure; regulatory requirements and regulatory developments;
success of Juno’s competitors with respect to competing treatments and
technologies; Juno’s dependence on third-party collaborators and other
contractors in Juno’s research and development activities, including for
the conduct of clinical trials and the manufacture of Juno’s product
candidates; Juno’s dependence on Celgene for the development and
commercialization outside of North America and China of Juno’s CD19
product candidates and any other product candidates for which Celgene
exercises an option; Juno’s dependence on JW Therapeutics (Shanghai)
Co., Ltd, over which Juno does not exercise complete control, for the
development and commercialization of product candidates in China; Juno’s
ability to obtain, maintain, or protect intellectual property rights
related to its product candidates; amongst others. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Juno’s business in general, see
Juno’s Annual Report on Form 10-Q filed with the Securities and Exchange
Commission on May 10, 2016 and Juno’s other periodic reports filed with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. Juno disclaims any obligation to
update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160804006311/en/